A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
Big progress vs cancer, folks.
The kind of event curves from randomized trials that we've not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done. #ASCO26, @ASCO
Huge thanks to @yliu_UofU and his stellar team for involving me and the @RutterLab in this work — what a cool story to be part of. Paper here: https://t.co/9ePJcKnjae
In Tripoli, I met Libya’s leaders, partners, and communities to advance solutions that protect people on the move.
Together, we are working on safe pathways, countering trafficking, and ensuring dignity for the most vulnerable.
Collaboration is key to lasting impact.
@svembu How many factors is a doctor able to look for in a patient … not too many, it is pattern matching at the end of the day. There needs to be a risk based adjustment to the current practice
Is the ECG secretly a sphygmomanometer? We trained a neural net to predict hypertension from ECGs and found it associated with many cardiovascular outcomes.